Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:INDP NASDAQ:OLMA NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$20.09-2.1%$20.08$16.65▼$31.26$905.23M0.91647,860 shs377,789 shsINDPIndaptus Therapeutics$3.58+0.3%$2.23$0.92▼$19.91$404.27M1.252.88 million shs587,061 shsOLMAOlema Pharmaceuticals$9.87+1.2%$14.06$3.89▼$36.26$851.64M1.981.35 million shs1.60 million shsPHARPharming Group$12.81-0.5%$14.67$9.54▼$21.34$909.65M-0.0411,006 shs6,849 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+1.18%+9.79%+17.31%+12.99%-21.19%INDPIndaptus Therapeutics+45.71%-24.84%+106.36%+101.69%-63.03%OLMAOlema Pharmaceuticals-0.71%-8.71%-30.21%-33.72%+138.97%PHARPharming Group+4.89%+3.29%-1.60%-11.23%+11.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$20.09-2.1%$20.08$16.65▼$31.26$905.23M0.91647,860 shs377,789 shsINDPIndaptus Therapeutics$3.58+0.3%$2.23$0.92▼$19.91$404.27M1.252.88 million shs587,061 shsOLMAOlema Pharmaceuticals$9.87+1.2%$14.06$3.89▼$36.26$851.64M1.981.35 million shs1.60 million shsPHARPharming Group$12.81-0.5%$14.67$9.54▼$21.34$909.65M-0.0411,006 shs6,849 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+1.18%+9.79%+17.31%+12.99%-21.19%INDPIndaptus Therapeutics+45.71%-24.84%+106.36%+101.69%-63.03%OLMAOlema Pharmaceuticals-0.71%-8.71%-30.21%-33.72%+138.97%PHARPharming Group+4.89%+3.29%-1.60%-11.23%+11.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.88Reduce$24.0019.46% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/AOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10346.81% UpsidePHARPharming Group 2.40Hold$38.33199.25% UpsideCurrent Analyst Ratings BreakdownLatest INDP, OLMA, PHAR, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.005/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026AMPHAmphastar Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$25.00 ➝ $21.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.23$4.16 per share4.83$17.17 per share1.17INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/APHARPharming Group$376.13M2.41$0.20 per share64.22$3.95 per share3.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.668.386.864.0411.00%15.12%7.14%8/6/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)PHARPharming Group$2.85M$0.1680.0719.71N/A3.30%4.64%2.55%7/30/2026 (Estimated)Latest INDP, OLMA, PHAR, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million3/17/2026Q4 2025INDPIndaptus Therapeutics-$4.36-$3.10+$1.26-$3.10N/AN/A3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/A3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82INDPIndaptus TherapeuticsN/A2.342.34OLMAOlema Pharmaceuticals0.0110.8810.88PHARPharming Group0.352.632.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%INDPIndaptus Therapeutics7.06%OLMAOlema Pharmaceuticals91.78%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%INDPIndaptus Therapeutics23.60%OLMAOlema Pharmaceuticals12.56%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableINDP, OLMA, PHAR, and AMPH HeadlinesRecent News About These CompaniesUS FDA accepts Pharming’s supplemental NDA resubmission for Joenja to treat children aged 4 to 11 years with APDSJune 6, 2026 | pharmabiz.comPPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 5, 2026 | markets.businessinsider.comPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 4, 2026 | globenewswire.comPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkJune 2, 2026 | finance.yahoo.comPharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | finanznachrichten.dePharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | manilatimes.netMPharming Group N.V. (PHAR) Shareholder/Analyst Call - SlideshowMay 28, 2026 | seekingalpha.comPharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndromeMay 26, 2026 | pharmabiz.comPEuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionMay 22, 2026 | markets.businessinsider.comPharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their ModelsMay 10, 2026 | finance.yahoo.comPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9, 2026 | theglobeandmail.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7, 2026 | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7, 2026 | markets.businessinsider.comPharming Group N.V. (PHAR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comPharming Group N.V. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comPharming earnings in focus: Can rare disease growth offset Q1 dip?May 6, 2026 | investing.comPharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6, 2026 | finance.yahoo.comPharming Group ADR PHGMay 5, 2026 | morningstar.comMHigh Growth Tech Stocks To Watch In May 2026May 5, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Pharming Group (PHAR) and Kura Oncology (KURA)April 24, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026Eli Lilly Wins Back CVS Health, Reverting Novo's AdvantageBy Leo Miller | June 2, 2026INDP, OLMA, PHAR, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$20.09 -0.44 (-2.14%) Closing price 04:00 PM EasternExtended Trading$20.09 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Indaptus Therapeutics NASDAQ:INDP$3.58 +0.01 (+0.28%) Closing price 04:00 PM EasternExtended Trading$3.50 -0.09 (-2.37%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Olema Pharmaceuticals NASDAQ:OLMA$9.87 +0.12 (+1.23%) Closing price 04:00 PM EasternExtended Trading$9.71 -0.16 (-1.61%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Pharming Group NASDAQ:PHAR$12.81 -0.07 (-0.54%) Closing price 04:00 PM EasternExtended Trading$13.00 +0.19 (+1.48%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
